| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285
The three peptides pancreatic polypeptide (PP), peptide YY (PYY), and neuropeptide Y (NPY) share a similar structure known as the PP-fold. There are four known human G-protein coupled receptors for the PP-fold peptides, namely Y1, Y2, Y4, and Y5, each of them being able to bind at least two of the three endogenous ligands. All three peptides are found in the circulation acting as hormones. Although NPY is only released from neurons, PYY and PP are primarily found in endocrine cells in the gut, where they exert such effects as inhibition of gall bladder secretion, gut motility, and pancreatic secretion. However, when PYY is administered in an experimental setting to animals, cloned receptors, or tissue preparations, it can mimic the effects of NPY in essentially all studies, making it difficult to study the effects of PP-fold peptides and to delineate what receptor and peptide accounts for a particular effect. Initial studies with transgenic animals confirmed the well-established action of NPY on metabolism, food-intake, vascular systems, memory, mood, neuronal excitability, and reproduction. More recently, using transgenic techniques and novel antagonists for the Y1, Y2, and Y5 receptors, NPY has been found to be a key player in the regulation of ethanol consumption and neuronal development.
Key Words: GPCR • knockout animal • distribution • mutagenesis • ligand binding
This article has been cited by other articles:
|
|
 |
|
  E. K. Jackson and Z. Mi Sitagliptin Augments Sympathetic Enhancement of the Renovascular Effects of Angiotensin II in Genetic Hypertension Hypertension, June 1, 2008; 51(6): 1637 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Bloom, F. P. Kuhajda, I. Laher, X. Pi-Sunyer, G. V. Ronnett, T. M.M. Tan, and D. S. Weigle The Obesity Epidemic: Pharmacological Challenges Mol. Interv., April 1, 2008; 8(2): 82 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Jackson, M. Zhang, W. Liu, and Z. Mi Inhibition of Renal Dipeptidyl Peptidase IV Enhances Peptide YY1 36-Induced Potentiation of Angiotensin II-Mediated Renal Vasoconstriction in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 431 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Kamiji and A. Inui Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity Endocr. Rev., October 1, 2007; 28(6): 664 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R39 - R46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Campbell, H. N. Lyon, J. Nemesh, J. A. Drake, T. Tuomi, D. Gaudet, X. Zhu, R. S. Cooper, K. G. Ardlie, L. C. Groop, et al. Association Studies of BMI and Type 2 Diabetes in the Neuropeptide Y Pathway: A Possible Role for NPY2R as a Candidate Gene for Type 2 Diabetes in Men Diabetes, May 1, 2007; 56(5): 1460 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Silva, J. Lourenco, S. Xapelli, R. Ferreira, H. Kristiansen, D. P. D. Woldbye, C. R. Oliveira, and J. O. Malva Protein kinase C activity blocks neuropeptide Y-mediated inhibition of glutamate release and contributes to excitability of the hippocampus in status epilepticus FASEB J, March 1, 2007; 21(3): 671 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ito, H. ThidarMyint, T. Murata, H. Inoue, R. M. Neyra, and H. Kuwayama Effects of peripheral administration of PYY3-36 on feed intake and plasma acyl-ghrelin levels in pigs. J. Endocrinol., October 1, 2006; 191(1): 113 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Movafagh, J. P. Hobson, S. Spiegel, H. K. Kleinman, and Z. Zukowska Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors FASEB J, September 1, 2006; 20(11): 1924 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Dubinion, Z. Mi, and E. K. Jackson Role of Renal Sympathetic Nerves in Regulating Renovascular Responses to Angiotensin II in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1330 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. B. Chaudhri, B. C. T. Field, and S. R. Bloom From gut to mind--hormonal satiety signals and anorexia nervosa. J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 797 - 798. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Dubinion, Z. Mi, C. Zhu, L. Gao, and E. K. Jackson Pancreatic Polypeptide-Fold Peptide Receptors and Angiotensin II-Induced Renal Vasoconstriction Hypertension, March 1, 2006; 47(3): 545 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Buckwalter, J. J. Hamann, and P. S. Clifford Neuropeptide Y1 receptor vasoconstriction in exercising canine skeletal muscles J Appl Physiol, December 1, 2005; 99(6): 2115 - 2120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dumont, E. Moyse, A. Fournier, and R. Quirion Evidence for the Existence of an Additional Class of Neuropeptide Y Receptor Sites in Rat Brain J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 99 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intravenous Infusion of Peptide YY(3-36) Potently Inhibits Food Intake in Rats Endocrinology, February 1, 2005; 146(2): 879 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lee, M. Hadi, G. Hallden, and G. W. Aponte Peptide YY and Neuropeptide Y Induce Villin Expression, Reduce Adhesion, and Enhance Migration in Small Intestinal Cells through the Regulation of CD63, Matrix Metalloproteinase-3, and Cdc42 Activity J. Biol. Chem., January 7, 2005; 280(1): 125 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Misra, K. S. Murthy, H. Zhou, and J. R. Grider Coexpression of Y1, Y2, and Y4 Receptors in Smooth Muscle Coupled to Distinct Signaling Pathways J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1154 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Comparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1064 - R1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Genetically Modified Animals in Endocrinology Endocr. Rev., August 1, 2004; 25(4): 673 - 677. [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Buckwalter, J. J. Hamann, H. A. Kluess, and P. S. Clifford Vasoconstriction in exercising skeletal muscles: a potential role for neuropeptide Y? Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H144 - H149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Horvath, S. Diano, and M. Tschop Brain Circuits Regulating Energy Homeostasis Neuroscientist, June 1, 2004; 10(3): 235 - 246. [Abstract] [PDF]
|
|
|
|
|
|
A. J. Rashid, B. F. O'Dowd, and S. R. George Minireview: Diversity and Complexity of Signaling through Peptidergic G Protein-Coupled Receptors Endocrinology, June 1, 2004; 145(6): 2645 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Berglund, D. A. Schober, M. A. Esterman, and D. R. Gehlert Neuropeptide Y Y4 Receptor Homodimers Dissociate upon Agonist Stimulation J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1120 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Berglund, D. A. Schober, M. A. Statnick, P. H. McDonald, and D. R. Gehlert The Use of Bioluminescence Resonance Energy Transfer 2 to Study Neuropeptide Y Receptor Agonist-Induced {beta}-Arrestin 2 Interaction J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 147 - 156. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
